focus -WSS

focus

author：comprehensive 2025-09-27 12:49:00 - browse：87268

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Congress needs to close a vaccine

WSS

What to know about a major upcoming Wegovy heart health study

STAT wants to know your pick for a great summer read or listen

Titanic submersible victims' family mourns: 'Enormous tragedy and devastation'

House panel to mark up pandemic

An outdated Medicare rule harms dementia patients with anxiety

Eli Lilly’s Zepbound improved liver scarring in mid

explore

focus

focus

The cancer drug shortage isn’t new — and neither are the solutions

Titanic submersible: What a 'catastrophic implosion' means and what officials found

Hollywood unions extend contract negotiations for actors

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Hepatitis C has a cure — but many Americans still lack access to it

What are cluster munitions? Biden defends decision to send controversial weapons to Ukraine

Tori Bowie and the unacceptable rates of Black maternal death

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

Activists slam private health insurers over coverage restrictions

Finland to offer bird flu vaccine to select groups of people, a possible global first

leisure time

FDA approves Moderna’s RSV vaccine, its second licensed product

With fresh data, a dynamic duo powers Eli Lilly to new heights

FDA approves Moderna’s RSV vaccine, its second licensed product

UPS workers' union leader explains what's at stake as strike edges closer

The most pressing bird flu mysteries scientists want answered

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

hotspot

focus

hotspot

Wikipedia